Claims for Patent: 7,638,488
✉ Email this page to a colleague
Summary for Patent: 7,638,488
Title: | Use of alpha-glucosidase inhibitors to treat alphavirus infections |
Abstract: | The present invention provides methods for treating a flavivirus infection, including hepatitis C virus (HCV) infection, in an individual suffering from a flavivirus infection. In some embodiments, the methods involve administering to an individual in need thereof an effective amount of an agent that inhibits enzymatic activity of a membrane-bound .alpha.-glucosidase inhibitor. In other embodiments, the methods involve administering to an individual in need thereof effective amounts of an .alpha.-glucosidase inhibitor and at least one additional therapeutic agent. |
Inventor(s): | Blatt; Lawrence M. (San Francisco, CA), Tan; Hua (Daly City, CA), Seiwert; Scott (Pacifica, CA) |
Assignee: | Intermune, Inc. (Brisbane, CA) |
Application Number: | 11/370,535 |
Patent Claims: | 1. A method of treating a flavivirus infection in an individual, the method comprising administering to an individual in need thereof an effective amount of an agent that
inhibits enzymatic activity of a membrane-bound .alpha.-glucosidase, wherein the agent is not an imino sugar.
2. The method of claim 1, wherein the agent inhibits the p7 protein of hepatitis C virus. 3. The method of claim 1, wherein the agent is acarbose or castanospermine. 4. A method of treating a flavivirus infection in an individual, the method comprising administering to an individual in need thereof effective amounts of an .alpha.-glucosidase inhibitor and at least one additional therapeutic agent, wherein the .alpha.-glucosidase inhibitor is not an imino sugar. 5. The method of claim 4, wherein the at least one additional therapeutic agent comprises an interferon-.alpha. (IFN-.alpha.). 6. The method of claim 5, wherein the IFN-.alpha. is interferon alfacon-1. 7. The method of claim 6, wherein the IFN-.alpha. is pegylated. 8. The method of claim 7, wherein the pegylated IFN-.alpha. is selected from peginterferon alfa-2a, peginterferon alfa-2b, and monoPEG (30 kD, linear)-ylated consensus IFN-.alpha.. 9. The method of claim 6, wherein the IFN-.alpha. is hyperglycosylated. 10. The method of claim 4, wherein the at least one additional therapeutic agent comprises an interferon-.gamma.(IFN-.gamma.). 11. The method of claim 10, wherein the IFN-.gamma. is interferon .gamma.-1b. 12. The method of claim 11, wherein the IFN-.gamma. is pegylated. 13. The method of claim 11, wherein the IFN-.gamma. is hyperglycosylated. 14. The method of claim 4, wherein the at least one additional therapeutic agent comprises an HCV NS3 protease inhibitor. 15. The method of claim 4, wherein the at least one additional therapeutic agent comprises an HCV NS5B RNA-dependent RNA polymerase inhibitor. 16. The method of claim 4, wherein the at least one additional therapeutic agent comprises a nucleoside analog. 17. The method of claim 16, wherein the nucleoside analog is selected from viramidine, ribavirin, and levovirin. 18. The method of claim 4, wherein the .alpha.-glucosidase inhibitor is acarbose or castanospermine. 19. The method of claim 1 or 4, wherein the .alpha.-glucosidase inhibitor is administered at a dosage selected from the group consisting of: about 10 mg--about 30 mg per day; about 30 mg--about 60 mg per day; about 10 mg three times daily; about 15 mg three times daily; and about 20 mg three times daily. 20. The method of any one of claims 1, 2, 3, 4-17 or 18, wherein the individual is a human. |
Details for Patent 7,638,488
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Kadmon Pharmaceuticals Llc | INFERGEN | interferon alfacon-1 | Injection | 103663 | 10/06/1997 | ⤷ Try a Trial | 2025-03-08 |
Horizon Therapeutics Ireland Dac | ACTIMMUNE | interferon gamma-1b | Injection | 103836 | 02/25/1999 | ⤷ Try a Trial | 2025-03-08 |
Merck Sharp & Dohme Corp. | PEGINTRON | peginterferon alfa-2b | Injection | 103949 | 01/19/2001 | ⤷ Try a Trial | 2025-03-08 |
Merck Sharp & Dohme Corp. | SYLATRON | peginterferon alfa-2b | For Injection | 103949 | 03/29/2011 | ⤷ Try a Trial | 2025-03-08 |
Zr Pharma& Gmbh | PEGASYS | peginterferon alfa-2a | Injection | 103964 | 10/16/2002 | ⤷ Try a Trial | 2025-03-08 |
Zr Pharma& Gmbh | PEGASYS | peginterferon alfa-2a | Injection | 103964 | 01/07/2004 | ⤷ Try a Trial | 2025-03-08 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.